Jump to main content
Jump to site search

Issue 6, 2013
Previous Article Next Article

Glucose conjugation for the specific targeting and treatment of cancer

Author affiliations

Abstract

Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

Graphical abstract: Glucose conjugation for the specific targeting and treatment of cancer

Back to tab navigation

Article information


Submitted
11 Dec 2012
Accepted
08 Apr 2013
First published
08 Apr 2013

Chem. Sci., 2013,4, 2319-2333
Article type
Minireview

Glucose conjugation for the specific targeting and treatment of cancer

E. C. Calvaresi and P. J. Hergenrother, Chem. Sci., 2013, 4, 2319
DOI: 10.1039/C3SC22205E

Social activity

Search articles by author

Spotlight

Advertisements